Evaluation of NBF Gingival Gel for treatment of inflammation in gums after cleaning of teeth by doctor and the effect on levels of anti-oxidants in saliva after using this gel.
Phase 4
Completed
- Conditions
- Health Condition 1: null- Chronic Marginal Gingivitis
- Registration Number
- CTRI/2018/01/011162
- Lead Sponsor
- Dr Abhinav Deshpande
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Age group between 20-60 years.
2. Patients in good systemic health.
3. Patients classified as stage II and stage III gingivitis based upon the gingival score given by Loe and Silness 1964.
4. Patients with minimum of 20 teeth.
5. Patients who had not received any type of periodontal therapy for the past 1 year.
Exclusion Criteria
1. Patients suffering from any systemic diseases or with compromised immune system.
2. Patients with a known history of drug allergy
3. Patients taking any drug known to cause gingival enlargement
4. Patients taking any immuno-suppressive drugs like corticosteroids.
5. Grade II and Grade III mobile teeth,
6. Pregnant and/or lactating mothers.
7. Patients with any bleeding disorders.
8. Patient on anticoagulant therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Gingival index (Loe and Silness-1964) <br/ ><br>2. Papilla bleeding index (Muhlemann-1977) <br/ ><br>3. Total Antioxidant capacity of SalivaTimepoint: 1. Gingival index (Loe and Silness-1964) recorded at baseline and 1 month post treatment. <br/ ><br>2. Papilla bleeding index (Muhlemann-1977)recorded at baseline and 1 month post treatment. <br/ ><br>3. Total Antioxidant capacity of Saliva recorded at baseline and 1 month post treatment.
- Secondary Outcome Measures
Name Time Method Total Antioxidant capacity of SalivaTimepoint: Total Antioxidant capacity of Saliva will be evaluated at baseline and 1 month after scaling.